Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units

Peter J. Choi, Hamish S. Sutherland, Amy S.T. Tong, Adrian Blaser, Scott G. Franzblau, Christopher B. Cooper, Manisha U. Lotlikar, Anna M. Upton, Jerome Guillemont, Magali Motte, Laurence Queguiner, Koen Andrés, Walter Van den Broeck, William A. Denny, Brian D. Palmer

Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Maurice Wilkins Centre, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA
Global Alliance for TB Drug Development, 40 Wall St, New York 10005, USA
Medicinal Chemistry Department (Infectious Diseases), Janssen Pharmaceuticals, Campus de Maigremont, BP315, 27106 Val de Reuil Cedex, France
Janssen Infectious Diseases BVBA, Beerse, Belgium

A R T I C L E   I N F O

Article history:
Received 7 September 2017
Revised 6 October 2017
Accepted 19 October 2017
Available online 20 October 2017

Keywords:
Bedaquiline
Bedaquiline analogues
Tuberculosis
Drug development

A B S T R A C T

Analogues of bedaquiline where the phenyl B-unit was replaced with monocyclic heterocycles of widely differing lipophilicity (thiophenes, furans, pyridines) were synthesised and evaluated. While there was an expected broad positive correlation between lipophilicity and anti-TB activity, the 4-pyridyl derivatives appeared to have an additional contribution to antibacterial potency. The majority of the compounds were (desirably) more polar and had higher rates of clearance than bedaquiline, and showed acceptable oral bioavailability, but there was only limited (and unpredictable) improvement in their hERG liability.

The often late detection of tuberculosis (TB), coupled with the need to use long and complex multi-drug treatment regimens, has led to an alarming increase in cases that are resistant to the standard front-line drugs (multi-drug-resistant; MDR). In 2016, about 580,000 new cases (3.9% of new cases and 21% of recurrent cases) were classified globally as MDR-TB, and this proportion has been rising rapidly.

Thus the discovery of bedaquiline (TMC207, Sirturo, Janssen Pharmaceuticals; Fig. 1; 1), a new TB drug, that, due to a novel mechanism of action (inhibition of the mycobacterial ATP synthase) is useful against drug-resistant tuberculosis (MDR-TB), has been of great significance. When added to standard background therapy used for MDR-TB, it demonstrated more rapid bactericidal activity than background therapy alone, and was approved by the US Food and Drug Administration in 2012 for the treatment of MDR-TB. However it is very lipophilic (measured logP 7.25), which likely contributes to its long terminal half-life of 5–6 months. The resultant potential for over-proportional accumulation in tissue has limited the full exploration of its potential dose range. More generally, highly lipophilic drugs also have a propensity for liver toxicity. Bedaquiline also shows inhibition of the hERG (human Ether-à-go-go-Related Gene; KCNH2) cardiac potassium channel, with the concomitant risk of delayed ventricular repolarization (QTc interval), and this is a point to be considered in the planning of combination regimens with other TB drugs with similar effects (e.g. fluoroquinolones, clofazimine).

Thus bedaquiline analogues of comparable antibacterial activity but with lower clogP and less potent inhibition of the hERG potassium channel, but similar in anti-Mtb potency to bedaquiline, would be of substantial interest. We have previously explored the effects of a range of more polar 6-substituents on the quinoline ring and showed that, on balance, a 6-CN group offered a significant reduction in overall lipophilicity over the standard 6-Br group (about 1.25 logP units) with the least deleterious effect on antibacterial potency.

In the current paper we explore the effects of replacing the phenyl B-ring unit of bedaquiline with heterocycles of differing lipophilicity. One example of such a heterocyclic analogue, the
3-furan 2 also with a smaller (phenyl) C-ring unit, (Fig. 1) has already been reported to show significant activity in M. smegmatis, with the separated racemic diastereomer pairs (configurations not assigned) having values of 1.57 and 0.06 μg/mL.11

The bedaquiline analogues were synthesized from appropriate Mannich base as above (see Supplementary Material for further details).

Scheme 1 shows the synthesis of the thienyl A/B-units and 64 to give the intermediate alcohols (selected from 55a–55j) gave compounds 15–21. The 3-furyl analogues 22–28 were synthesized by preparation of the boronic acid 68 (from 51) and Suzuki coupling of this and 3-(bromomethyl) furan 69 to give A/B-unit 70, and subsequent condensation with the appropriate Mannich base as above (see Supplementary Material for further details).

Schemes 3 and 4 outline the syntheses of the B-ring unit pyridyl compounds 29–50. In Scheme 3, Suzuki coupling of boronic acid 68 and 2-(chloromethyl)-6-methoxypyridine (71) gave A/B-unit 72, which was condensed with Mannich bases 55a, 55b and 55f and 55l to give compounds 29, 30 and 33 of Table 1. Similar reaction of 68 with bromides 82 and 83 gave respectively A/B-units 84 and 85, which yielded compounds 38 and 39 of Table 1. Compound 35 was prepared by Suzuki coupling of quinoline 51 with aldehyde 73 to give the resulting hydroxyl intermediate 74. Mesylation followed by reduction of 74 afforded the A/B-unit 75. Likewise, compounds 36 and 37 were prepared by Suzuki coupling of quinoline 51 with aldehydes 76 and 77 to give the resulting hydroxy intermediates 78 and 79. Lewis acid mediated deoxygenation of these gave A/B-units 79 and 80 respectively. All of these A/B-units were
Scheme 2. Classes E and F (compounds 15–28). Reagents and conditions: (i) LiTMP, B(OiPr)₃; (ii) Et₃SiH, TFA, DCM, 20 °C, 1 h; (iii) LDA, THF, –75 °C, 1.5 h then appropriate ketone 55, –75 °C, 4 h; (iv) Pd(PPh₃)₄, Cs₂CO₃, toluene/DMF, 90 °C, 5 h.

Scheme 3. Class G (compounds 29–39). Reagents and conditions: (i) Pd(PPh₃)₄, Cs₂CO₃, toluene/DMF, reflux; (ii) LDA, THF, –75 °C, 1.5 h then appropriate ketone 55, –75 °C, 4 h; (iii) LiTMP, THF, –75 °C, 1.5 h then appropriate aldehyde, –75 °C, 4 h; (iv) MsCl, Et₃N, DMF, then NaBH₄; (v) NaBH₄, AlCl₃.
condensed with Mannich base 55f to give the target compounds (see Supplementary Material for further details).

In Scheme 4, similar Suzuki coupling of boronic acid 68 with chlorides 86, 88 and 90 gave A/B-units 87, 89 and 91. These were condensed with the appropriate Mannich bases to give compounds 40–45 and 47–50 of Table 1 (see Supplementary Material for further details).

Some of the C/D-unit Mannich bases required have been previously reported. New analogues were prepared either via the Mannich reaction from the corresponding acetoephones or the Grignard reaction from the corresponding Weinreb amides as shown in Scheme 5 (see Supplementary Material for further details).

For comparison of 6-Br and 6-CN substituents in the A-unit, several Br analogues (6, 9, 15, 22, 30, 33, 45) were converted directly to the corresponding CN compounds (7, 10, 16, 23, 31, 34, 46) (Scheme 6). We have previously shown that the optimum conditions for this reaction are aryl bromide (1 equiv), zinc (0.1 equiv), zinc (II) cyanide (0.55 equiv), tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) (0.1 equiv), and tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) (0.1 equiv) followed by addition of the appropriate Mannich bases 55a–j (−78 °C, 3–4 h, then AcOH) under previously-reported conditions gave racemic mixtures of two diastereomers (see Supplementary Material for further details). This mixture was purified by column chromatography to >95% purity in-house, and the desired RS, SR enantiomer was then separated from the mixture by preparative super-critical fluid HPLC at BioDuro LLC (Beijing). The coupling yields for classes E–H appear to be higher than classes A–D, although this comparison is complicated by the small sample sizes in classes B, C and D. Moreover, in some cases, the coupling reaction proceeded in high conversion, but due to difficulty in purifying the product from impurities the final yield was reduced. There is however, an apparent correlation between the electron density at the benzylic position of the A/B-unit and the yield of the reaction. The best coupling unit (E) is a 2-substituted furan which exerts a strong electron donating effect towards the benzylic position. While the second best unit (G) is a more electron withdrawing pyridine, the 2 or 4-substituted electron donating substituent contributes some electron density towards the benzylic position. Unit H has a 4-aza atom which renders the benzylic position less electron rich, despite a 2-methoxy substituent, and the average coupling yield is even lower. These observations suggest that the lithium anion formed at the benzylic position could be more nucleophilic with a higher electron donation from the B-ring, making the A/B-unit more reactive and favouring the coupling reaction.

The compounds were evaluated for their inhibition of growth (measured as MIC90 values in μg/mL) against M. tuberculosis (strain H37Rv) under both replicating (MABA) or non-replicating (LORA) conditions. Under these conditions bedaquiline (1) is a potent inhibitor of both (MICs 0.05 and 0.08 μM respectively). In a previous structure-activity relationship (SAR) study of bedaquiline analogues it was shown that electron-withdrawing groups, especially F or Cl at the 3- and 4-positions on the phenyl B-ring unit (Fig. 1) provided compounds with better MICs against M. tuberculosis, but at the expense of even higher overall lipophilicity. In a search for less lipophilic analogues, we prepared and evaluated compounds where this phenyl B-ring unit was replaced with different
### Table 1

Bedaquiline analogues containing heterocyclic ring units.

| No | R          | X (Class) | Y                  | MIC<sub>90</sub> (μg/mL)<sup>a</sup> | clogP<sub>b</sub> |
|----|------------|-----------|--------------------|--------------------------------------|------------------|
|    |            |           |                    | MABA | LORA |
| 1  | Br         | Phenyl    | 2,3-Benz           | 0.05 | 0.08 | 7.25  |
| 2  | Br         | A         | 3-CN               | 0.12 | 0.12 | 6.10  |
| 3  | Br         | A         | 2,3-DiOMe          | 0.50 | 0.54 | 6.33  |
| 4  | Br         | A         | 2-Aza, 3-OMe       | 0.12 | 0.15 | 5.99  |
| 5  | Br         | A         | 3-Aza, 5-Me        | 0.58 | 0.30 | 5.67  |
| 6  | CN         | A         | 3-Aza, 3-Me        | 1.94 | 1.10 | 4.24  |
| 7  | Br         | A         | 3-Aza, 2-OMe       | 0.12 | 0.20 | 5.99  |
| 8  | Br         | B         | 3-F                | 0.06 | 0.11 | 6.81  |
| 9  | CN         | B         | 3-F                | 0.05 | 0.20 | 4.67  |
| 10 | Br         | C         | 3-F                | 0.47 |        |       |
| 11 | Br         | C         | 3-Aza, 2-OMe       | 0.22 | 0.52 | 5.55  |
| 12 | Br         | D         | 3-Aza, 2-OMe       | 0.24 | 0.53 | 5.09  |
| 13 | CN         | D         | 3-F                | 0.70 |        |       |
| 14 | Br         | E         | 3-F                | 0.74 |        | 5.40  |
| 15 | CN         | E         | 3-F                | 1.79 |        | 4.02  |
| 16 | Br         | E         | 3-OCF<sub>3</sub>  | 0.76 |        | 7.51  |
| 17 | Br         | E         | 2,3-DiOMe          | 0.71 |        | 6.14  |
| 18 | Br         | E         | 2,3-OCH<sub>2</sub>O- | 0.69 |        | 6.45  |
| 19 | Br         | E         | 2-Aza              | 1.95 |        | 4.98  |
| 20 | Br         | E         | 3-CN               | 1.96 |        | 4.69  |
| 21 | Br         | F         | 3-F                | 0.74 |        | 5.40  |
| 22 | CN         | F         | 3-F                | 1.08 |        | 4.04  |
| 23 | Br         | F         | 2-Aza, 3-F         | 0.68 |        | 5.00  |
| 24 | Br         | F         | 3-OCF<sub>3</sub>  | 0.76 |        | 7.30  |
| 25 | Br         | F         | 2,3-DiOMe          | 1.16 |        | 5.93  |
| 26 | Br         | F         | 2,3-OCH<sub>2</sub>O- | 0.90 |        | 6.23  |
| 27 | Br         | F         | 2-Aza              | 1.80 |        | 4.77  |
| 28 | Br         | F         | 2-Aza              | 1.80 |        | 4.77  |
| 29 | Br         | G; Z = 2-OMe | 3-F               | 0.12 |        | 5.14  |
| 30 | Br         | G; Z = 2-OMe | 3-Me              | 0.13 | 0.25 | 5.50  |
| 31 | CN         | G; Z = 2-OMe | 3-Me              | 0.30 | 0.15 | 4.16  |
| 32 | Br         | G; Z = 2-OMe | 2,3-DiOMe         | 0.24 |        | 4.66  |
| 33 | Br         | G; Z = 2-OMe | 3-CN              | 0.34 | 0.75 | 4.43  |
| 34 | CN         | G; Z = 2-OMe | 3-CN              | 0.38 | 0.82 | 3.07  |
| 35 | Br         | G; Z = 2-NMe<sub>2</sub> | 3-F        | 0.18 | 0.20 | 5.44  |
| 36 | Br         | G; Z = 4-NMe<sub>2</sub> | 3-F     | 0.08 | 0.15 | 5.44  |
| 37 | Br         | G; Z = 4-NEt<sub>2</sub> | 3-F   | 0.02 | 0.02 | 6.49  |
| 38 | Br         | G; Z = 4-SMe | 3-F             | 0.14 | 0.37 | 5.86  |
| 39 | Br         | G; Z = 4-SEt | 3-F           | 0.14 | 0.15 | 6.39  |
| 40 | Br         | G; Z = 5-Me | 3-OMe            | 1.9  | 2.2  | 5.00  |
| 41 | Br         | G; Z = 5-Me | 3-CN             | 1.32 | 3.38 | 4.51  |
| 42 | Br         | G; Z = 5-Me | 3-F              | 0.53 | 0.97 | 5.22  |
| 43 | Br         | G; Z = 4.5-diOMe | 3-F     | 0.47 | 0.54 | 5.59  |
| 44 | Br         | H; Z = 2,3-diOMe | 3-F     | 0.02 | 0.07 | 5.19  |
| 45 | Br         | H; Z = 2,3-diOMe | 3-Me    | 0.02 | 0.04 | 5.55  |
| 46 | CN         | H; Z = 2,3-diOMe | 3-Me   | 0.15 | 0.14 | 4.19  |
| 47 | Br         | H; Z = 2,3-diOMe | 3-OCF<sub>3</sub>H | <0.02 | <0.02 | 5.00  |
| 48 | Br         | H; Z = 2,3-diOMe | 3-OCF<sub>3</sub>H | <0.02 | <0.02 | 5.41  |
| 49 | Br         | H; Z = 2,3-diOMe | 3-CN    | 0.13 | 0.21 | 4.48  |
| 50 | Br         | H; Z = 2,3-diOMe | 2,3-DiOMe | 0.21 |        | 4.71  |

<sup>a</sup> MIC<sub>90</sub> (μg/mL): minimum inhibitory concentration for 90% inhibition of growth of Mtb strain H37Rv, determined under aerobic (replicating; MABA) (Ref. 16) or non-replicating (LORA) (Ref. 17) conditions, determined at the Institute for Tuberculosis Research, University of Illinois at Chicago. Each value is the mean of at least two independent determinations.

<sup>b</sup> clogP calculated by ChemDraw Ultra v12.0.2. (CambridgeSoft).

<sup>c</sup> RS/SR racemic mixture.

<sup>d</sup> MICs determined at Tibotec (Mechelen, Belgium).
heterocycles of varying lipophilicity (Table 1). A representative subset of compounds were also evaluated for a number of pharmacological properties, and compared against bedaquiline (1) (Table 2).

Compounds 3–10 explore the use of dimethylthiophene B-ring units. While these are slightly more lipophilic than benzene, the set of compounds prepared had clogP values lower than bedaquiline (between 6.33 and 4.24) and MABA MICs between 0.05 and 0.58 μg/mL. The exception was the much less lipophilic CN derivative 7 (clogP 4.24), which was less active. The 2,3-dimethylthiophene 9, bearing a more lipophilic 3-F C-unit substituent, had comparable activity to 1 and its cyano counterpart 10, with a much lower clogP (4.67) was equally potent. The 2-Me and 2-OMe thiophenes 12 and 13 were also effective inhibitors, despite clogP values of around 5.

Given that good activity had been reported for furan 2 (albeit in M. smegmatis),11 we evaluated a series of both 2- and 3-furyl analogues bearing different C-unit substituents. For the whole dataset (49 compounds, including 1), despite a wide variation in structure and some MICs being determined using a slightly different protocol (see Table 1), there was a modest positive correlation between potency and lipophilicity (Eq. (1)), as was shown previously for both bedaquiline derivatives 10 and other classes of M. tb inhibitors.18

\[
\log \text{MIC} = -0.53\log \text{P} + 1.96 \\
(1)
\]

The 2-furyl (15–21) and 3-furyl (22–28) compounds had a relatively narrow range of potencies (MICs 0.68–1.96 μg/mL), despite a wide lipophilicity range (clogPs from 7.51 to 4.02). For this subgroup of similar compounds, high lipophilicity (clogP) correlated with higher potency (MIC) (Eq. (1)). Compounds 29–43 of Table 1.
explored a variety of 3-pyridyl B-ring units. The clogP values of these again ranged quite widely (from 6.49 to 3.07) but as a class they were more potent than the other B-unit heterocycle compounds, with the majority having MICs < 0.5 μg/mL in both MABA and LORA assays. Finally, the small cohort of 4-pyridyl analogues (44–50) appeared even more potent, with MICs < 0.05 μg/mL in both assays yet with clogP values around 5 (significantly better than that of 1). Thus it is possible to go against the overall trend of a positive correlation between MIC and lipophilicity with compounds such as 47 and 48, which retain the potency of 1 yet have a clogP lower by 2.25 units. This was shown earlier by studying compounds with varying 6-substituents in the A-ring unit quinoline, where the polar CN substituent lowered overall clogP by 3.07, despite its significantly lower lipophilicity. Indeed, all of the compounds in Table 2 had acceptable bioavailability.

Conclusions

This work, part of a study exploring analogues of 1 with an altered profile of biological properties, has focused on the effects of replacing the phenyl B-ring unit of bedaquiline with heterocycles of differing lipophilicity, in compounds with a smaller C-ring unit; thiophene-, furan- and pyridyl-based B-ring units were studied. In addition to the expected broad positive correlation between lipophilicity and anti-TB potency (Eq. (1)), the 3-pyridyl and especially the 4-pyridyl compounds did seem to have an additional measure of potency, suggesting that further exploration of the B-unit region might be fruitful.